Skip to main content

Table 5 Adjusted* healthcare cost (€) per patient per year by antimuscarinic drug

From: Health economics perspective of fesoterodine, tolterodine or solifenacin as first-time therapy for overactive bladder syndrome in the primary care setting in Spain

Resource, mean (95% CI†)

Antimuscarinic

 
 

Fesoterodine

Solifenacin

Tolterodine

PValue*

 

(n = 302)

(n = 952)

(n = 717)

 

Medical visits

433 (411; 457)

533 (515; 552)‡

563 (539; 585)‡§

<0.001

Primary care

268 (249; 290)

300 (284; 319)‖

329 (305; 353)‡§

0.005

Specialist

152 (144; 162)

212 (208; 216)‡

204 (200; 207)§¶

<0.001

Emergency room

12 (10; 16)

21 (19; 24)‡

30 (27; 33)§¶

<0.001

Analytical tests

18 (15; 20)

17 (15; 18)

16 (14; 18)

0.686

X-ray

6 (5; 8)

7 (6; 7)

8 (7; 9)

0.157

Complementary tests

7 (5; 10)

7 (5; 8)

8 (5; 10)

0.849

Hospital stays

35 (19; 59)

46 (33; 63)

53 (41; 70)

0.509

Antimuscarinic drugs

740 (690; 796)

626 (602; 652)‡

624 (597; 650)‡

<0.001

Concomitant medication#

216 (180; 258)

305 (274; 338)‡

335 (306; 366)‡

0.001

Absorbents

187 (135; 244)

243 (201; 290)

289 (237; 344)‖

0.094

Total healthcare costs

1639 (1542;1725)

1780 (1699; 1854)‖

1893 (1815; 1969)‡§

0.003

  1. *Controlling for location, age, sex, medication possession ratio, time since diagnosis and Charlson co-morbidity index.
  2. †95% bootstrap confidence interval bias corrected.
  3. ‡ P < 0.01 vs fesoterodine.
  4. § P < 0.05 vs solifenacin.
  5. ‖ P < 0.05 vs fesoterodine.
  6. P < 0.01 vs solifenacin.
  7. #Includes OAB-related medication use (anti-depressants, benzodiazepines, hypnotics, laxatives, anti-infective drugs).
Back to article page

BMC Urology

ISSN: 1471-2490

Contact us